University of Alberta
Edmonton, Alberta, T6G 2S8, Canada
Location status: Recruiting
Location contact
Michelle C Carbonneau, MN NP
CONTACT
Puneeta Tandon, MD
CONTACT
NCT Number: NCT04149223
Liver cirrhosis is the leading cause of morbidity and premature mortality in patients with digestive disease. There are many gaps in care which contribute to a high rate of hospital readmissions (44 percent at 90 days) and inadequate quality of care. Currently, there is a lack of structured processes to initiate best practice support for medical and broader health needs of high risk patients.
The cirrhosis care Alberta program (CCAB) is a 3 year multi-component quality improvement initiative which will aim to improve quality of care, reduce acute care utilization and be satisfactory to both patients and providers. Best practice support will be provided in the areas of: Evidence based management of cirrhosis, alcohol use support, frailty, advance care planning, home-hospital-home transitions including standardized outpatient monitoring and structured urgent access for rapid, on-demand outpatient assessment.
Interested in participating?
Request Info18 year and older
All sexes
Interventional
Not applicable
Edmonton, Alberta, T6G 2S8, Canada
Location status: Recruiting
Michelle C Carbonneau, MN NP
CONTACT
Puneeta Tandon, MD
CONTACT
Cirrhosis Care Alberta (CCAB) is a 3 year multi-component system-wide quality improvement trial which aims to improve quality of care, reduce acute care utilization and meet the needs of both patients and providers throughout Alberta. Instead of addressing just a single contributor to acute care utilization, this ambitious intervention will be the first in the world to bring together care providers across the province to tackle the complex multilevel problem with a multilevel solution. The intervention includes implementation of our standardized integrated strategy for delivering evidence-based best practices under real-world conditions to address the key determinants of hospital readmission and length of stay (LOS) in patients admitted with cirrhosis.
The CCAB project intervention includes:
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
o Adult patients who do not have cirrhosis
Standardized order sets for guidance in ascites, varices, hepatic encephalopathy, infections, and medication reconciliation (optimizing HE medication, medication prophylaxis, withdrawal of non-indicated proton pump inhibitors).
Time frame: Baseline, 1 year, 2 year
LOS
Time frame: Baseline,through study completion, an average of 1 year
Readmission rate
Time frame: Baseline,through study completion, an average of 1 year
LOS
Time frame: From commencement of the study (baseline), assessed quarterly until study completion.
Readmission rate
Time frame: Baseline,through study completion, an average of 1 year
ED visit rate
Time frame: Baseline,through study completion, an average of 1 year
by provider type, location
Time frame: Baseline,through study completion, an average of 1 year
Patient with cirrhosis survival
Time frame: Baseline,through study completion, an average of 1 year
laboratory values, model for end-stage liver disease (MELD) score
Time frame: From commencement of the study (baseline), assessed quarterly until study completion.
Adherence to cirrhosis order set
Contact information is provided by the study sponsor or research team.
Michelle Carbonneau, MN, NP
CONTACT
Puneeta Tandon, MD
CONTACT
University of Alberta
Other
Cirrhosis Care Alberta (CCAB): A Pragmatic Type II Hybrid Effectiveness Implementation Trial Evaluating the Effectiveness of a Standardized Order Set
Acronym: CCAB
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05832229
Alcohol-Induced Disorders, Alcohol-Related Disorders
La Jolla, California, United States
View Trial DetailsNCT06136221
Atrophy, Behavior
Ann Arbor, Michigan, United States
View Trial DetailsNCT06950788
Cirrhosis, Liver, Diabetes Mellitus Risk
Chicago, Illinois, United States
View Trial DetailsNCT05623150
Adenocarcinoma, Alcohol-related Liver Disease
Nice, France
View Trial Details